Successful receptor-mediated radiation therapy of xenografted human midgut carcinoid tumour by Kölby, L et al.
Successful receptor-mediated radiation therapy of xenografted
human midgut carcinoid tumour
LK o ¨lby*,1, P Bernhardt
2, V Johanson
1, A Schmitt
2, H Ahlman
1, E Forssell-Aronsson
2,HM a ¨cke
3 and O Nilsson
4
1Department of Surgery, Lundberg Laboratory for Cancer Research, Institute for Surgical Sciences, Go ¨teborg University, Sahlgrenska University Hospital,
Go ¨teborg SE-413 45, Sweden;
2Department of Radiation Physics, Lundberg Laboratory for Cancer Research, Go ¨teborg University, Sahlgrenska University
Hospital, Go ¨teborg, Sweden;
3Division of Radiological Chemistry, University Hospital, Basel, Switzerland;
4Departments of Pathology, Lundberg Laboratory
for Cancer Research, Go ¨teborg University, Sahlgrenska University Hospital, Go ¨teborg, Sweden
Somatostatin receptor (sstr)-mediated radiation therapy is a new therapeutic modality for neuroendocrine (NE) tumours. High
expression of sstr in NE tumours leads to tumour-specific uptake of radiolabelled somatostatin analogues and high absorbed doses. In
this study, we present the first optimised radiation therapy via sstr using [
177Lu-DOTA
0-Tyr
3]-octreotate given to nude mice
xenografted with the human midgut carcinoid GOT1. The tumours in 22 out of 23 animals given therapeutic amounts showed dose-
dependent, rapid complete remission. The diagnostic amount (0.5MBq [
177Lu-DOTA
0-Tyr
3]-octreotate) did not influence tumour
growth and was rapidly excreted. In contrast, the therapeutic amount (30MBq [
177Lu-DOTA
0-Tyr
3]-octreotate) induced rapid
tumour regression and entrapment of
177Lu so that the activity concentration of
177Lu remained high, 7 and 13 days after injection.
The entrapment phenomenon increased the absorbed dose to tumours from 1.6 to 4.0GyMBq
 1 and the tumours in animals
treated with 30MBq received 120Gy. Therapeutic amounts of [
177Lu-DOTA
0-Tyr
3]-octreotate rapidly induced apoptosis and
gradual development of fibrosis in grafted tumours. In conclusion, human midgut carcinoid xenografts can be cured by receptor-
mediated radiation therapy by optimising the uptake of radioligand and taking advantage of the favourable change in biokinetics
induced by entrapment of radionuclide in the tumours.
British Journal of Cancer (2005) 93, 1144–1151. doi:10.1038/sj.bjc.6602845 www.bjcancer.com
Published online 25 October 2005
& 2005 Cancer Research UK
Keywords: carcinoid; GOT1; somatostatin receptors; [
177Lu-DOTA
0-Tyr
3]-octreotate; therapy
                                                   
Midgut carcinoids are the most frequent neuroendocrine (NE)
tumours of the gastrointestinal tract and often present with
widespread disease and severe hormonal symptoms (Modlin et al,
2003). These tumours have high expression of somatostatin
receptors (sstr), which can be exploited for diagnostic and
therapeutic purposes (Nilsson et al, 1998). The most sensitive
method to detect carcinoid metastases is sstr scintigraphy using
111In coupled with the somatostatin analogue octreotide via the
chelator DTPA (Krenning et al, 1993; Ahlman et al, 1994; Cimitan
et al, 2003). Pharmacological treatment of the carcinoid syndrome
with long-acting somatostatin analogues reduces hormone release
and related symptoms in the majority of patients. However, there
is no evidence that somatostatin analogues exert antiproliferative
actions on these tumours, although individual cases with induction
of apoptosis have been reported (Eriksson and O ¨berg, 1999; O ¨berg,
1999; Bousquet et al, 2001). The only curative treatment for
carcinoid tumours is surgical, but due to late diagnosis, radical
surgery is seldom possible. Debulking procedures offer palliation
of hormonal symptoms and may prolong survival (McEntee et al,
1990; Ahlman et al, 2000). Palliative treatment may include
chemotherapy and biotherapy with interferon, both with limited
benefits and adverse effects (O ¨berg, 1993; Moertel et al, 1994;
Ko ¨lby et al, 2003). Following interventional and medical treatment,
the 5-year survival is as high as 69% for patients with liver
metastases (Wa ¨ngberg et al, 1996; Hellman et al, 2002).
A new treatment strategy is directed radiation therapy with
radiolabelled somatostatin analogues. The first therapies were
attempted with [
111In-DTPA
0]-octreotide and resulted in reduced
tumour markers such as chromogranin A (CgA, the general NE
marker) and 5-hydroxy indole acetic acid (5-HIAA, the serotonin
metabolite), but only occasionally objective tumour responses
(Fja ¨lling et al, 1996; McCarthy et al, 1998; Krenning et al, 1999).
111In emits mainly photons that will cause a high whole body
irradiation, which limits its use for therapy (Bernhardt et al, 2001).
111In also emits Auger electrons with extremely short range with
the potential to cause cell death, if the radionuclide can be
allocated to the nucleus (Bernhardt et al, 2003b). Using the high-
energy beta emitter
90Y, coupled to [Tyr
3]-octreotide via the
chelator DOTA (1,4,7,10-tetraazacyclododecane,1,4,7,10-tetraacetic
acid), partial tumour remission was achieved in 7–24% of the
patients (Paganelli et al, 2001; Waldherr et al, 2001; Valkema et al,
2002). Development of new somatostatin analogues with higher
receptor affinity and higher degree of receptor internalisation will
improve the therapeutic efficacy. The new somatostatin-based
radioligand [DOTA
0,Tyr
3,Thr
8]-octreotide (¼[DOTA
0,Tyr
3]-
octreotate) has a higher affinity for sstr2 than [DOTA
0,Tyr
3]-
octreotide, and coupled with the medium-energy b-emitter
177Lu,
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shigh absorbed doses can be achieved (de Jong et al, 1997; Reubi
et al, 2000; de Jong et al, 2001).
177Lu has a shorter range than
90Y
and is therefore better suited for therapy of smaller tumours
(Bernhardt et al, 2001; Bernhardt et al, 2003a). Previous
experimental studies with xenografts have been performed using
rat pancreatic acinar tumours carrying sstr, while the GOT1 model
is an authentic human carcinoid with preserved phenotype (de
Jong et al, 1998, 2001; Ko ¨lby et al, 2001). In a recent series, patients
with large NE tumour burden were treated with [
177Lu-DOTA
0-
Tyr
3]-octreotate and partial tumour regression was seen in 35%
and complete remission in 3% (Kwekkeboom et al, 2003).
In the present study, we analysed the effect of treatment with
[
177Lu-DOTA
0-Tyr
3]-octreotate of the human midgut carcinoid
GOT1 xenografted to nude mice. Our aims were to optimise the
uptake of [
177Lu-DOTA
0-Tyr
3]-octreotate by defining the point of
receptor saturation following a single i.v. injection of the radio-
pharmaceutical and to evaluate the effect of sstr-mediated
radiation therapy with [
177Lu-DOTA
0-Tyr
3]-octreotate given to
xenografted midgut carcinoid tumours.
MATERIAL AND METHODS
Animal model
The transplantable human midgut carcinoid GOT1 was established
as previously described (Ko ¨lby et al, 2001). In brief, cultured GOT1
cells were inoculated subcutaneously into nude mice. After 6
months, tumours became visible. These tumours were minced into
pieces and new generations of tumours were generated by
transplantation of tumour tissue to the subcutis of nude mice.
When the tumours were 5–10mm in size, the experiments were
started. The experiments were approved by the Ethical Committee
for Animal Research at Go ¨teborg University. All animal procedures
were consistent with the animal use guidelines of the UKCCCR.
Pharmaceuticals
Kits of [DOTA
0-Tyr
3]-octreotate were made by mixing 2.02mg
[DOTA
0-Tyr
3]octreotate (synthesized by Jo ¨rg Schmitt, Division of
Radiological Chemistry, University Hospital, Basel, Switzerland)
with 630mg sodium ascorbate (VWR International AB, Sweden),
125mg gentisic acid (2,5-dihydroxy benzoic acid; VWR Interna-
tional AB, Sweden) and 5ml 0.05 M HCl. Each kit contained 40mg
of [DOTA
0-Tyr
3]-octreotate. The compound was stored at  251C
until use.
177LuCl3 (Perkin Elmer, Life Sciences, Inc., Boston, MA,
USA) was diluted in 0.05 M HCl and mixed with [DOTA
0-Tyr
3]-
octreotate to a specific activity of 30MBqmg
 1. For the biokinetic
studies with 0.5MBq [
177Lu-DOTA
0-Tyr
3]-octreotate, the specific
activity was 0.5MBqmg
 1. The mixture was incubated for 30min at
801C (de Jong et al, 2001).
[DTPA]-octreotide was labelled with
111In according to the
manufacturer’s instructions (Mallinckrodt Medical B.V., The
Netherlands).
The peptide-bound fraction of
177Lu and
111In was assessed by
instant thin layer chromatography (ITLC-SG, Gelman, Ann Arbor,
MI, USA) with 0.1 M sodium citrate (pH¼5.0, VWR International
AB, Sweden) as mobile phase. The fraction of peptide-bound
177Lu
and
111In was more than 99%.
The exact amount of radiopharmaceutical administered was
determined by measuring the activity in the syringes before and
after administration of the radiopharmaceutical with a well-type
ionisation chamber (CRC-15R, Capintec, NJ, USA).
Biodistribution and biokinetics of
[
177Lu-DOTA
0-Tyr
3]-octreotate
For studies of the biodistribution of [
177Lu-DOTA
0-Tyr
3]-octreo-
tate, five groups of tumour-bearing animals were injected with a
single i.v. injection of 7.5, 15, 30, 60 and 120MBq of
177Lu-DOTA-
Tyr
3-octreotate (30MBqmg
 1), respectively (n¼5 in all groups).
The animals were killed 24h later and tumour tissue and multiple
organs were collected for measurement of radioactivity and
histopathological analyses. The
177Lu activity was measured using
a Wallac 1480 gamma counter (WIZARD
s300, Wallac, Oy,
Finland). Correction was made for detector background and
radioactive decay. The activity concentration (C) of the radio-
nuclide was expressed as the fraction of injected activity per unit
mass of the tissue (%IAg
 1).
For studies of biokinetics, tumour-bearing animals were injected
with 0.5MBq (1mg, n¼20) or 30MBq (1mg, n¼20) [
177Lu-
DOTA
0-Tyr
3]-octreotate, that is, diagnostic and therapeutic
amounts of radionuclide, respectively. All animals were injected
with a single i.v. injection and were killed in groups of five at 1, 3, 7
and 13 days post injection (p.i.), respectively. Control animals
(n¼5) were untreated. Tumour tissue and multiple organs were
collected for measurements of radionuclide uptake and histo-
pathological analyses.
The activity concentration (%IAg
 1) was determined for
tumour tissue (CT) and normal tissue (CN). The tumour-to-normal
tissue activity concentration ratio (TNC) was calculated according
to the formula TNCN¼CT/CN.
Dosimetry
The calculation of the absorbed dose to tumours, kidneys, liver
and bone marrow was based on the pharmacokinetics of 0.5 and
30MBq [
177Lu-DOTA
0-Tyr
3]-octreotate (Loevinger, 1988). The
cumulative activity concentration, that is, the total number of
radioactive decays per mass unit, was determined by estimating
the area under the curve for the activity concentration in each
organ vs time. The electron energy emitted per decay was assumed
to be 147keV (Sowby, 1983). The contribution from photons was
neglected. Also, the contribution from organs other than the target
organ was neglected.
Therapeutic effects of
177Lu-DOTA-Tyr
3-octreotate
The therapeutic effect of
177Lu-octreotate was studied in five groups
of tumour-bearing animals given 7.5 (0.25mg, n¼6), 15 (0.5mg,
n¼6), 30 (1mg, n¼6), 60 (2mg, n¼7) or 120 (4mg, n¼10)MBq of
[
177Lu-DOTA
0-Tyr
3]-octreotate, respectively. Control animals
(n¼11) were given 4mg of [DOTA-Tyr
3]-octreotate. Tumour size
was measured and the volume was calculated according to the
formula V¼4pab
2/3 (a is the longest radius and b is the transverse
radius). The animals were followed for 2–7 months. Complete
response (CR) was defined as 499% reduction of tumour volume.
Partial response (PR) was defined as 50–99% reduction and minor
response (MR) as o50% reduction of tumour volume.
Biodistribution of [
111In-DTPA]-octreotide
In order to make it possible to compare the uptake of radiolabelled
somatostatin analogue with previous clinical studies, the binding
of radiolabelled octreotide was investigated. Each animal (n¼5)
was injected i.v. with 4MBq (0.2mg) of [
111In-DTPA]-octreotide
24h before killing. Tumours and blood samples were collected and
weighed, and the
111In activity in tumour and blood was measured
using the gamma counter. The TNCBlood was calculated as
described above (Forssell-Aronsson et al, 1995).
Morphological analysis
Morphological analysis was carried out on all tumours included in
this study to verify potential therapeutic effects. Tumour tissue
from all animals were harvested and fixed in 4% paraformaldehyde
(PF) in PBS at pH 7.4 for 24h. Specimens were subsequently
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sdehydrated and embedded in paraffin wax. Parallel sections were
counterstained with haematoxylin (htx) and eosin for morpholo-
gical analysis, and with Ladewig staining to facilitate the detection
of fibrin thrombi in tumour vessels. In all animals given a
therapeutic amount of [
177Lu-DOTA
0-Tyr
3]-octreotate, micro-
scopic examination of liver, kidneys and bone marrow was
performed in order to reveal any morphological changes related
to radiation. Deparaffinised sections were preincubated with 5%
nonfat dry milk followed by incubation overnight with primary
antibodies, listed in Table 1. Antiserum was diluted in PBS
containing 1% BSA and 0.1% sodium azide. Bound antibodies
were visualised by the indirect immunoperoxidase technique
(EnVisiontþ, cat. no. K4000, Dakopatts, Glostrup, Denmark).
Apoptotic cell count
The number of apoptotic tumour cells was investigated in tumour
tissue from the biokinetic study (animals injected with 30MBq
177Lu-octreotate and followed up to 13 days). Haematoxylin–
eosin-stained sections were used to identify apoptotic tumour cells
according to morphological criteria (condensed and fragmented
nuclei and eosinophilic cytoplasma). Three high power fields
(HPF;  40 objective) were selected from each tumour for
counting of apoptotic cells. To obtain representative areas of the
tumour, a direction from the centre to the periphery of the tumour
was randomly selected. Photographs of each HPF were then
systematically taken: (i) in the centre, (ii) half way to the periphery
and (iii) in the periphery of the tumour, all along the selected line.
The number of apoptotic cells was counted on the photographs
and the average number of apoptotic cells per HPF calculated
(apoptotic cell count).
Statistical analysis
Differences between groups regarding uptake of [
177Lu-DOTA
0-
Tyr
3]-octreotate, TNC value and apoptotic cell count were analysed
by one-way analysis of variance. Logarithmic transformation
was used for variance stabilisation. Compensation for multiple
comparisons was performed using the Dunnett’s method
(Hochberg and Tamane, 1987).
Differences in biokinetics between 30 and 0.5MBq were analysed
by two-way analysis of variance followed by t-test at each time
point. Logarithmic transformation was used for variance stabilisa-
tion. Compensation for mass significance was performed accord-
ing to Bonferroni-Holm (Hochberg and Tamane, 1987).
For analysis of the therapeutic effect of [
177Lu-DOTA
0-Tyr
3]-
octreotate, the number of CR in the treatment groups (7.5–
120MBq) was compared to the number of CR in the control group
using Fisher’s exact test. Compensation for mass significance was
performed according to Bonferroni-Holm.
P-values o0.05 were considered significant.
RESULTS
Biodistribution of [
177Lu-DOTA
0-Tyr
3]-octreotate
Five groups of tumour-bearing animals were given 7.5, 15, 30, 60
and 120MBq [
177Lu-DOTA
0-Tyr
3]-octreotate, respectively. The
maximum uptake of [
177Lu-DOTA
0-Tyr
3]-octreotate in GOT1
tumours 24h p.i. was seen both in animals given 7.5 and 15MBq
and reached 1773% IAg
 1 (mean7s.e.m.). In animals given
larger amounts of activity, the uptake declined, indicating
saturation of sstr in tumour tissue.
In normal tissues, the uptake was generally lower than in
tumours. The highest uptake was found in the kidneys (6.1–
7.7%IAg
 1) (Figure 1). For all other organs (liver, spleen, small
intestine, blood, skeletal muscle, heart, brain, lungs, pancreas and
adrenals), the uptake was very low (0.01–1.7) %IAg
 1. For
kidneys, liver, blood, skeletal muscle, heart and brain, the uptake
was independent of the amount of activity administered, which
indicates no saturation, or nonspecific distribution in the tissues.
However, in the spleen, small intestine, lungs, pancreas and
adrenals, the uptake was highest for 7.5MBq [
177Lu-DOTA
0-Tyr
3]-
octreotate and declined with increasing amounts of [
177Lu-DOTA
0-
Tyr
3]-octreotate, which indicates saturation of receptor-mediated
binding.
Biokinetics of [
177Lu-DOTA
0-Tyr
3]-octreotate
In order to compare the biokinetics of [
177Lu-DOTA
0-Tyr
3]-
octreotate after diagnostic and therapeutic amounts, two groups of
animals were injected with 0.5 and 30MBq [
177Lu-DOTA
0-Tyr
3]-
octreotate, respectively. The specific activity of [
177Lu-DOTA
0-
Tyr
3]-octreotate in the diagnostic group was lower, that is, the
amount of peptide (1mg) was identical in both groups.
The uptake of [
177Lu-DOTA
0-Tyr
3]-octreotate in tumours was
similar for both groups of animals 24h p.i. However, the
biokinetics of the activity concentration differed significantly
between the two groups. In animals given 0.5MBq [
177Lu-DOTA
0-
Tyr
3]-octreotate, which did not retard tumour growth, the activity
concentration declined over time and was less than 50% at 7 days
and less than 20% at 13 days p.i. compared to the initial
concentration. In contrast, in animals given 30MBq, the activity
concentration remained high over time and the biokinetic curves
differed significantly both at 7 days p.i. (P¼0.00044) and 13 days
p.i. (P¼0.00081) (Figure 2). The tumour volumes at 7 days p.i. and
13 days p.i. for animals given 30MBq were reduced to 1678.5 and
1174.2% (mean7s.e.m.) compared to the initial volumes.
Tumour-to-normal tissue activity concentration ratio
Tumour-to-normal tissue activity concentration ratios of [
177Lu-
DOTA
0-Tyr
3]-octreotate were determined up to 13 days after a
single injection of 30MBq. In general, the TNC value increased
compared to the situation at 24h p.i., which indicates a favourable
change over time for the radiation to the tumour in relation to
the radiation received by liver, kidneys and bone marrow. The
increase in TNC value at 7 days p.i., compared to 24h p.i., was
significant for the bone marrow (P¼0.0031), liver (P¼0.033) as
well as for the kidneys (P¼0.00015) (Figure 3).
Dosimetry
Tumours treated with 30MBq received about 120Gy, correspond-
ing to 4.0GyMBq
 1, when the absorbed dose was calculated using
biokinetic data for the therapeutic amount of 30MBq. For normal
Table 1 Primary antibodies used for immunocytochemistry
Antibody Dilution Clone Cat. no Company
CgA (monoclonal, anti-human) 1:1000 LK2H10 1199021 Boehringer Mannheim, Mannheim, Germany
Ki-67 (monoclonal, anti-human) 1:100 MIB-1 DAKO, Glostrup, Denmark
CD 3 (monoclonal, anti-human) 1:100 M7254 DAKO, Glostrup, Denmark
CD 20 (M-20, goat anti-mouse) 1:50 Sc-7735 Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA
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stissues in animals given 30MBq, the absorbed doses were 0.15Gy
to bone marrow, 0.68Gy to liver and 8.7Gy to kidneys,
respectively. The diagnostic amount 0.5MBq, with clearly different
biokinetics, resulted in 1.6GyMBq
 1 to the tumours.
Therapeutic effects of [
177Lu-DOTA
0-Tyr
3]-octreotate
Five groups of tumour-bearing animals were injected with 7.5, 15,
30, 60 and 120MBq
177Lu-DOTA-Tyr
3-octreotate, respectively.
Control animals were given 4mg of unlabelled DOTA-Tyr
3-
octreotate. The tumours in control animals grew rapidly and
doubled their volumes after 2 weeks. Treatment with [
177Lu-
DOTA
0-Tyr
3]-octreotate resulted in a rapid and dose-dependent
reduction of tumour volume (Figure 4). The number of CR
increased significantly with increasing amounts of [
177Lu-DOTA
0-
Tyr
3]-octreotate administered (Table 2).
After treatment with 30MBq, one out of six animals with CR
remained free of recurrent tumour until being killed 3 months
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Figure 1 Uptake of [
177Lu-DOTA
0-Tyr
3]-octreotate was studied in tumours as well as in several organs 24h p.i. In the tumours, the maximum uptake
was 1773.3%IAg
 1 (mean7s.e.m. n¼5 for all groups) and was seen in animals receiving 15MBq (0.5mg) and 7.5MBq (0.25mg) [
177Lu-DOTA
0-Tyr
3]-
octreotate. Decreasing uptake for higher administered doses indicated saturation of sstr in tumour tissue. For the critical organs kidney and liver, no signs of
saturation was seen. P-values reflect the difference vs 7.5MBq.
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Figure 2 The biokinetics of [
177Lu-DOTA
0-Tyr
3]-octreotate after a
diagnostic amount (0.5MBq) as well as after a therapeutic amount
(30MBq) was studied in two groups of animals injected with [
177Lu-
DOTA
0-Tyr
3]-octreotate. In the animals receiving 0.5MBq [
177Lu-DOTA
0-
Tyr
3]-octreotate, the activity concentration declined over time. On the
contrary, in animals receiving 30MBq, the activity concentration was
retained over time and the biokinetic curves differed significantly both at 7
days p.i. (P¼0.00044) and 13 days p.i. (P¼0.00081). The values are
presented as mean7s.e.m., n¼5 at all time points for both groups.
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Figure 3 Tumour-to-normal tissue activity concentration ratio (TNC) of
[
177Lu-DOTA
0-Tyr
3]-octreotate followed up to 13 days after a single
injection of 30MBq. At 3, 7 and 13 days p.i., the TNC value increased
compared to the situation 1 day p.i. This indicates a favourable relation over
time for the radiation to the tumour in comparison with the radiation to
the critical organs liver, kidney and bone marrow. P-values reflect the
difference vs 1 day p.i.
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Figure 4 Treatment with [
177Lu-DOTA
0-Tyr
3]-octreotate resulted in a
rapid, dose-dependent reduction of tumour volume. For animals receiving
7.5 and 15MBq, the effect was moderate and temporary, whereas for
animals receiving 30MBq CR was achieved. In animals treated with 30, 60
or 120MBq, 22 out of 23 animals had CR. The tumour volume presented is
the mean volume7s.e.m. for each group, set to 1 at the start of the
experiment. The P-values for the number of CR for animals treated with
30, 60 and 120MBq vs controls are 0.00032, 0.0011 and 0.000014,
respectively.
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slater. After 60MBq, two out of six animals with CR remained free
of recurrence until being killed 6 –7 months later. After treatment
with 120MBq, six out of 10 animals with CR remained free of
recurrence until being killed 3–4 months after the remission
(Figure 4).
Biodistribution of [
111In-DTPA]-octreotide
The activity concentration of [
111In-DTPA]-octreotide in GOT1
tumours 24h p.i. was 8.272.0%IAg
 1 (mean7s.e.m.). The
TNCBlood for [
111In-DTPA]-octreotide was then 410770
(mean7s.e.m.).
Induction of apoptosis and necrosis after treatment with
[
177Lu-DOTA
0-Tyr
3]-octreotate
In untreated controls, tumour cells grew in solid sheets with small
variation in nuclear size and without necroses. The tumour cells
were positive for the general NE-marker CgA, serotonin (5-HT)
and Vesicular Mono Amine Transporters (VMAT1 and 2). In
animals treated with 30MBq [
177Lu-DOTA
0-Tyr
3]-octreotate, a
significant increase in apoptotic cell count, compared to controls,
was observed both at 1 day p.i. (P¼0.0000030) and 3 days p.i.
(P¼0.00000059). In animals killed 3 days p.i., all five tumours had
large confluent necroses and intercellular oedema. In animals,
killed 7 and 13 days p.i., the number of tumour cells was clearly
reduced as was the apoptotic cell count and the oedema and
necroses were replaced by fibrosis. The typical appearance of a
tumour 13 days p.i. was that of almost complete fibrosis and
absence of tumour cells (Figure 5). The apoptotic cell count at each
time point is presented in Figure 5F.
In the therapy groups (7.5–120MBq), all tumours, or tumour
residues, were morphologically examined at the end of the
observation period. Gross examination of the small residual
tumour tissue, found in animals with CR in response to [
177Lu-
DOTA
0-Tyr
3]-octreotate, revealed brownish nodules, 1–2mm in
diameter. The microscopic analysis demonstrated a thin rim of
fibroblasts in the periphery and a central part consisting of
crystalline structures surrounded by inflammatory cells including
macrophages and giant cells (Figure 6). Specific staining for fibrin
(Ladewig) did not show any signs of thrombosis in treated
tumours.
Side effects of radiation
Morphologic analysis of the liver, kidneys and bone marrow after
[
177Lu-DOTA
0-Tyr
3]-octreotate therapy revealed two animals with
reactive inflammatory response in the portal fields of the liver.
These inflammatory infiltrates were composed both of CD 3-
positive T cells and CD 20-positive B cells and had a Ki-67
proliferative index of o1%. In one animal, the kidney contained a
fibrous scar. The bone marrow of all animals was normal with
preserved haematopoietic cells.
DISCUSSION
This study presents the first systematic optimisation of sstr-
mediated radiation therapy with [
177Lu-DOTA
0-Tyr
3]-octreotate of
a human midgut carcinoid xenografted to nude mice. The first part
of the study demonstrated that saturation of sstr in the tumours
after a single i.v injection of [
177Lu-DOTA
0-Tyr
3]-octreotate was
evident between 0.5mg (15MBq) and 1mg (30MBq). It is important
to define this level, since suboptimal therapeutic amounts will
not lead to maximal uptake and maximal absorbed doses in the
tumours. The uptake, and hence the absorbed dose, in the kidneys,
liver and bone marrow increased proportionally to the amounts
administered. Therefore, amounts in excess of the tumour
saturation level will increase adverse effects of radiation therapy.
The second part of the study described the markedly different
biokinetics of [
177Lu-DOTA
0-Tyr
3]-octreotate, given in diagnostic
vs therapeutic amounts. The activity concentration in tumours
after being given diagnostic amounts (0.5MBq, 1mg) was reduced
over time. On the other hand, in tumours from animals given a
therapeutic amount (30MBq, 1mg), the concentration remained
high over time and significantly differed from the animals given a
diagnostic amount both at 7 and 13 days p.i. The preserved high
activity concentration in the therapy group was unexpected and
significantly contributed to the high absorbed doses in the
tumours, and thereby a very high efficacy of the radiation therapy.
The difference in biokinetics can to a large extent be explained by
tumour shrinkage, but other factors may also be of importance, for
example, upregulation of sstr expression, radionuclide sequestra-
tion, increased intratumoural pressure and changed tumour blood
flow initiated by the radiation.
The entrapment of radionuclide and altered biokinetics in the
tumours after a therapeutic amount resulted in significantly
increased TNC values over time. Therefore, choice of a radio-
nuclide with half-life long enough to take advantage of this
favourable change is essential when sstr-mediated radiation
therapy is planned.
The third part of the study showed dose-dependent tumour
responses. In animals treated with 7.5 and 15MBq [
177Lu-DOTA
0-
Tyr
3]-octreotate, the absorbed doses were low and CR was seen
only occasionally. These tumours started to grow again after 2
weeks of reduced volume. In animals treated with 30–120MBq
[
177Lu-DOTA
0-Tyr
3]-octreotate, the absorbed doses were high; all,
but one, of these animals showed CR. It is very unusual to obtain
CR in animal tumour models using radionuclide therapy. Besides
the present study and our previous study on [
177Lu-DOTA
0-Tyr
3]-
octreotate therapy in the human small-cell lung cancer cell line
NCI-H69 xenografted to nude mice, CR is very unusual (de Jong
et al, 2001; Schmitt et al, 2004). For a long period, carcinoid
Table 2 Result of therapy with [
177Lu-DOTA
0-Tyr
3]-octreotate
Administered amount
of
177Lu-DOTA-Tyr
3-
octreotate
Complete response
(CR), 499% reduction
of tumour volume,
P-value vs controls
Partial response (PR)
50–99% reduction of
tumour volume
Minor response (MR)
o50% reduction of
tumour volume
0MBq, n¼11 (controls) 0 0 0
7.5MBq, n¼6 0 NS 3 3 (33–46% reduction)
15MBq, n¼6 2 NS 3 1 (49% reduction)
30MBq, n¼66 P¼0.00032 — —
60MBq, n¼76 P¼0.0011 1 (98% reduction) —
120MBq, n¼10 10 P¼0.000014 —
NS¼nonsignificant.
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stumours were considered to be resistant to radiation therapy.
However, a palliative role for both external radiation and
131I-
MIBG radiation therapy of NE tumours was proposed some 10
years ago (Samlowski et al, 1986; Kimmig, 1994). The present
study clearly shows that human midgut carcinoid xenografts can
be cured by adequate radiation therapy with minimal adverse
effects.
Sstr-mediated radiation therapy using [
177Lu-DOTA
0-Tyr
3]-
octreotate in clinical series of patients with large tumour burden
has not resulted in high rates of CR, most probably due to the
administration of suboptimal amounts of radiopharmaceutical
(Kwekkeboom et al, 2003). Our experiments show the importance
of defining the amount of peptide required to achieve receptor
saturation. This should, therefore, be included as part of the dose
planning before therapy. Also correct choice of radionuclide and
somatostatin analogue is of importance to obtain a high absorbed
dose, which is a pre-requisite for a good tumour response
(Bernhardt et al, 2001; Bernhardt et al, 2003a).
The present study not only showed a high cure rate of human
midgut carcinoids but also revealed an unexpected entrapment of
177Lu in tumour tissue during therapy. As recently shown in a
patient with limited lymphoglandular spread of midgut carcinoid
tumour, [
177Lu-DOTA
0-Tyr
3]-octreotate has the potential to
induce almost complete remission (Ahlman et al, 2004). GOT1
cells were harvested from the first patient, who underwent therapy
with [
111In-DTPA]-octreotide. The biological characteristics of
GOT1 closely resemble the tumour of the original patient, that is,
preserved neuroendocrine differentiation and molecular markers,
0
5
10
15
20
25
30
35
A
p
o
p
t
o
t
i
c
 
c
e
l
l
 
c
o
u
n
t
Time p.i. (days)
C1371 3
F
Figure 5 Typical morphological appearance of GOT1 tumours 1 day (B), 3 days (C), 7 days (D) and 13 day (E) after treatment with 30MBq [
177Lu-
DOTA
0-Tyr
3]-octreotate compared to an untreated tumour (A). After injection of [
177Lu-DOTA
0-Tyr
3]-octreotate, significant increases in the apoptotic
cell count vs controls could be seen both 1 day p.i. (P¼0.0000030) and 3 day p.i. (P¼0.00000059). At 3 days p.i., all five tumours presented with large
confluent necroses and oedema. At 7 and 13 days p.i., the apoptotic cell count decreased and the oedema and necroses were gradually replaced by fibrosis.
The apoptotic cell count was 1.970.29 (mean7s.e.m.) for control animals and 2674.3, 2973.1, 1.270.65 and 070 at 1, 3, 7 and 13 days p.i., respectively
(F). Typically, apoptotic cells (condensed and fragmented nuclei and eosinophilic cytoplasma) are indicated by arrows. Scale bar equals 20mm.
Figure 6 Histopathological analysis of a small remnant of tumour tissue
in an animal with CR 5 months after administration of 120MBq [
177Lu-
DOTA
0-Tyr
3]-octreotate. The tumour residue consisted of a brownish
nodule (2mm in diameter). In the periphery, only a thin rim of fibroblasts
was found. The dominant part of the nodule contained crystalline
structures surrounded by inflammatory cells including macrophages and
giant cells. Scale bar equals 1mm.
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spreserved sstr expression and a TNCBlood value of about 400 for
[
111In-DTPA]-octreotide uptake (Fja ¨lling et al, 1996; Ko ¨lby et al,
2001). In other aspects, that is, subcutaneous tumour localisation
and more rapid tumour growth, the model differs from the human
situation. An orthotopic model, with liver metastases, would be
very helpful to further resemble the clinical situation. The
exceptional results obtained in GOT1 xenografts may thus indicate
a possibility for more successful treatment of patients with
metastatic carcinoid tumours than hitherto achieved in clinical
series. In the individual patient, determination of sstr expression
profiles in tumours by real-time quantitative PCR may be helpful
to select the best somatostatin analogue to obtain maximal uptake
of the radiopharmaceutical. Also, a radionuclide with suitable
range in relation to the volumes of the tumours intended to be
treated is important (Bernhardt et al, 2001). Determination of the
specific uptake in tumours (studied in biopsies or determined by
octreotide scintigraphy) can also be helpful to estimate the
absorbed dose and expected biological effect (Forssell-Aronsson
et al, 1995). In the future, the dose dependency of the shown
entrapment as well as the tolerance of normal tissues to sstr-
mediated radiation therapy must be studied in detail before this
type of treatment can be transferred to the clinical situation with
high success rate.
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